Brian Rini, MD, FASCO

Christopher Wallis, MD, PhD, FRCSC

GU Oncology Now

<p>Brian Rini, MD, FASCO, Vanderbilt-Ingram Cancer Center, and Christopher Wallis, MD, PhD, University of Toronto, discuss the results of a late-breaking abstract on KEYNOTE-426, which now has long-term survival data available for pembrolizumab plus axitinib versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma.<p><a href="https://guoncologynow.com/category/asco-2023" target="_blank" rel="noopener">View more ASCO 2023 videos</a>.</p></p>


Drs. Rini, Wallis on a 5-Year Analysis of KEYNOTE-426 for Advanced Clear Cell RCC

American Society of Clinical Oncology 2023 Annual Meeting

ASCO 2023

Drs. Rini and Wallis discuss the results of a late-breaking abstract on KEYNOTE-426, which now has long-term survival data.

Drs. Rini, Wallis on a 5-Year Analysis of KEYNOTE-426

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe